Listed pharmas reduces R&D investments to overcome weakened profitability

Published: 2016-11-17 09:09:49

Updated: 2016-11-17 09:09:49

Since some pharmaceutical companies’ profitability has been weakened, their short-sighted business management, which decreases investments in R&D, has been criticized.

According to the analysis result of the KOSPI and KOSDAQ listed pharmaceutical companies’ 2015 3^rd quarter performances, their R&D expense/sales ratio was 7.9% by the 3^rd quarter.

The researched pharmaceutical companies’ 2014 &...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.